|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: Report of incidence and mortality in China cancer
registries, 2009. Chin J Cancer Res. 25:10–21. 2013.
|
|
3
|
Oba K, Paoletti X, Bang YJ, Bleiberg H,
Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP,
et al: Role of chemotherapy for advanced/recurrent gastric cancer:
an individual-patient-data meta-analysis. Eur J Cancer.
49:1565–1577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopan R and Ilagan MX: The canonical Notch
signaling pathway: unfolding the activation mechanism. Cell.
137:216–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borggrefe T and Liefke R: Fine-tuning of
the intracellular canonical Notch signaling pathway. Cell Cycle.
11:264–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
South AP, Cho RJ and Aster JC: The
double-edged sword of Notch signaling in cancer. Semin Cell Dev
Biol. 23:458–464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai Q, Andreu-Agullo C, Insolera R, Wong
LC, Shi SH and Lai EC: BEND6 is a nuclear antagonist of Notch
signaling during self-renewal of neural stem cells. Development.
140:1892–1902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mullendore ME, Koorstra JB, Li YM,
Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A
and Feldmann G: Ligand-dependent Notch signaling is involved in
tumor initiation and tumor maintenance in pancreatic cancer. Clin
Cancer Res. 15:2291–2301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bolos V, Mira E, Martinez-Poveda B, Luxan
G, Canamero M, Martinez-A C, Manes S and de la Pompa JL: Notch
activation stimulates migration of breast cancer cells and promotes
tumor growth. Breast Cancer Res. 15:R542013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piazzi G, Fini L, Selgrad M, Garcia M,
Daoud Y, Wex T, Malfertheiner P, Gasbarrini A, Romano M, Meyer RL,
et al: Epigenetic regulation of Delta-Like1 controls Notch1
activation in gastric cancer. Oncotarget. 2:1291–1301.
2011.PubMed/NCBI
|
|
11
|
Wang Z, Li Y and Sarkar FH: Notch
signaling proteins: legitimate targets for cancer therapy. Curr
Protein Pept Sci. 11:398–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Y, Gao X, Liu J, Kong QY, Wang XW,
Chen XY, Wang Q, Cheng YF, Qu XX and Li H: Differential Notch1 and
Notch2 expression and frequent activation of Notch signaling in
gastric cancers. Arch Pathol Lab Med. 135:451–458. 2011.PubMed/NCBI
|
|
13
|
Li DW, Wu Q, Peng ZH, Yang ZR and Wang Y:
Expression and significance of Notch1 and PTEN in gastric cancer.
Ai Zheng. 26:1183–1187. 2007.(In Chinese).
|
|
14
|
Li X, Ma Q, Xu Q, Duan W, Lei J and Wu E:
Targeting the cancer-stroma interaction: a potential approach for
pancreatic cancer treatment. Curr Pharm Des. 18:2404–2415. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shuman Moss LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899.
2012.PubMed/NCBI
|
|
16
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li T, Kon N, Jiang L, Tan M, Ludwig T,
Zhao Y, Baer R and Gu W: Tumor suppression in the absence of
p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell.
149:1269–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng HH, Kuo CC, Yan JL, Chen HL, Lin WC,
Wang KH, Tsai KK, Guven H, Flaberg E, Szekely L, et al: Control of
cyclooxygenase-2 expression and tumorigenesis by endogenous
5-methoxytryptophan. Proc Natl Acad Sci USA. 109:13231–13236. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Moraes E, Dar NA, de Moura Gallo CV and
Hainaut P: Cross-talks between cyclooxygenase-2 and tumor
suppressor protein p53: balancing life and death during
inflammatory stress and carcinogenesis. Int J Cancer. 121:929–937.
2007.PubMed/NCBI
|
|
20
|
Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC,
Li AF, Wang AM, Kuo ML and Chi CW: The activated Notch1 signal
pathway is associated with gastric cancer progression through
cyclooxygenase-2. Cancer Res. 69:5039–5048. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Portanova P, Notaro A, Pellerito O,
Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores
TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and
DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol.
43:121–130. 2013.PubMed/NCBI
|
|
22
|
Zhou H, Luo Y, Chen JH, Hu J, Luo YZ, Wang
W, Zeng Y and Xiao L: Knockdown of TRB3 induces apoptosis in human
lung adenocarcinoma cells through regulation of Notch 1 expression.
Mol Med Rep. 8:47–52. 2013.PubMed/NCBI
|
|
23
|
Kristoffersen K, Villingshoj M, Poulsen HS
and Stockhausen MT: Level of Notch activation determines the effect
on growth and stem cell-like features in glioblastoma multiforme
neurosphere cultures. Cancer Biol Ther. 14:625–637. 2013.
View Article : Google Scholar
|
|
24
|
Yabuuchi S, Pai SG, Campbell NR, de Wilde
RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M,
Maitra A and Rajeshkumar NV: Notch signaling pathway targeted
therapy suppresses tumor progression and metastatic spread in
pancreatic cancer. Cancer Lett. 335:41–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang H, An HJ, Song JY, Kim TH, Heo JH,
Ahn DH and Kim G: Notch3 and Jagged2 contribute to gastric cancer
development and to glandular differentiation associated with MUC2
and MUC5AC expression. Histopathology. 61:576–586. 2012.PubMed/NCBI
|
|
26
|
Nicolas M, Wolfer A, Raj K, Kummer JA,
Mill P, van Noort M, Hui CC, Clevers H, Dotto GP and Radtke F:
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet.
33:416–421. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fanjul-Fernandez M, Folgueras AR, Fueyo A,
Balbin M, Suarez MF, Fernandez-Garcia MS, Shapiro SD, Freije JM and
Lopez-Otin C: Matrix metalloproteinase Mmp-1a is dispensable for
normal growth and fertility in mice and promotes lung cancer
progression by modulating inflammatory responses. J Biol Chem.
288:14647–14656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaimal R, Aljumaily R, Tressel SL, Pradhan
RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S and Agarwal
A: Selective blockade of matrix metalloprotease-14 with a
monoclonal antibody abrogates invasion, angiogenesis, and tumor
growth in ovarian cancer. Cancer Res. 73:2457–2467. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi H, Xu JM, Hu NZ and Xie HJ: Prognostic
significance of expression of cyclooxygenase-2 and vascular
endothelial growth factor in human gastric carcinoma. World J
Gastroenterol. 9:1421–1426. 2003.PubMed/NCBI
|
